Pharma firm Venus Treatments on Saturday stated it has registered a 9.22 per cent enhance in annual gross sales in 2021-22 compared to gross sales in 2020-21.
“Aided by concerted efforts to construct on its export orders, provide chain, distribution community and product portfolio, the annual gross sales of Venus Treatments grew from Rs 548.12 crore in FY2020-21 to Rs 598.65 crore this fiscal (2021-22),” the corporate stated in an announcement right here.
The Panchkula-based firm additionally reported a 16.81 per cent enhance in working revenue, which went up from Rs 53.78 crore final fiscal to Rs 62.82 crore in 2021-22.
Saransh Chaudhary, president, International Crucial Care, Venus Treatments Ltd, stated, Embarking on product diversification with the launch of a full-fledged client healthcare division, we expanded the scope of our enterprise to make it an increasing number of sustainable in the long term.
“We additionally enhanced our international presence in FY 2021-22 by getting into into extra territories and launching greater than 30 merchandise in our present markets.
Venus Treatments entered a number of new international markets like Macedonia, the UAE, Ghana, Rwanda, Turkmenistan, Moldova, Eire, Cuba, Kurdistan, Kuwait and Turkmenistan and Cameroon in 2021-22, stated the assertion.
Chaudhary stated the corporate additionally accelerated its efforts to consolidate on its provide chain and distribution community in 2021-22 to basically strengthen its enterprise on sustainable traces and lend it extra stability within the wake of pricing pressures brought on by components like hike in gas costs, implications of the Russia-Ukraine struggle, rising API prices and disruption in provide chain within the aftermath of Covid restrictions.
On the corporate’s outlook for the present monetary yr, Chaudhary stated Venus Treatments can be diversification to boost its profitability, which might be aided by a extra secure pricing atmosphere this yr.
This will likely be complimented by the corporate’s continued give attention to constructing a sturdy product pipeline consisting of a balanced mixture of generic and analysis and development-based medication, he stated.